Cipla gets USFDA nod for generic acid reflux drug

The company has received final approval for its abbreviated new drug
application (ANDA) for Esomeprazole for oral suspension in the
strengths of 10mg, 20mg and 40mg from the United States Food and Drug
Administration (USFDA), Cipla said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-gets-usfda-nod-for-generic-acid-reflux-drug/articleshow/74824762.cms

Comments

Popular posts from this blog

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission

Biotecnika Times – Newsletter 25.01.2021 – CSIR Notice, CSIR-CCMB & ILS Hiring, FSSAI Funded